0001808255-20-000001.txt : 20200401 0001808255-20-000001.hdr.sgml : 20200401 20200401162421 ACCESSION NUMBER: 0001808255-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200401 DATE AS OF CHANGE: 20200401 EFFECTIVENESS DATE: 20200401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galavant Therapeutics, Inc. CENTRAL INDEX KEY: 0001808255 IRS NUMBER: 845129487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-364151 FILM NUMBER: 20765719 BUSINESS ADDRESS: STREET 1: 155 JEFFERSON DRIVE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-268-4252 MAIL ADDRESS: STREET 1: 155 JEFFERSON DRIVE, SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 D 1 primary_doc.xml X0708 D LIVE 0001808255 Galavant Therapeutics, Inc. 155 JEFFERSON DRIVE, SUITE 100 MENLO PARK CA CALIFORNIA 94025 650-268-4252 DELAWARE None None Corporation true 2020 Jonathan Waldstreicher c/o Galavant Therapeutics, Inc. 155 Jefferson Street, Suite 100 Menlo Park CA CALIFORNIA 94025 Executive Officer Director Seth Harrison c/o Galavant Therapeutics, Inc. 155 Jefferson Street, Suite 100 Menlo Park CA CALIFORNIA 94025 Director Biotechnology Decline to Disclose 06b false 2020-03-20 false true false 0 100000 100000 0 false 1 0 0 0 false Galavant Therapeutics, Inc. /s/ Jonathan Waldstreicher Jonathan Waldstreicher President & CEO 2020-03-30